We first simulated these GBM-associated mutations in response to 20 ng/mL EREG, which led to the prediction of a stronger, more gradual signaling response in GBM-associated mutants compared to the wild-type receptor, reminiscent of the difference between EGF and EREG responses (Figure 3D). The gene discussed is EGF; the disease is glioblastoma.